COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study on Lixisenatide and Counterregulation to Hypoglycemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02020629
Recruitment Status : Completed
First Posted : December 25, 2013
Last Update Posted : December 15, 2015
Information provided by (Responsible Party):
Bo Ahren, Lund University

Brief Summary:
In hypoglycemia, there is a counterregulation to restore glucose levels. An important part of this counterregulation is the release of the hormone glucagon. Since the GLP-1 receptor agonist lixisenatide has been shown to be associated with a low risk of hypoglycemia, this study examines whether lixisenatide affects the glucagon response to hypoglycemia.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Drug: Lixisenatide Phase 4

Detailed Description:
The study is a single-center, randomized, placebo-controlled study with a cross-over design and examines the glucagon response during a hyperinsulinemic hypoglycemic phase after a 6-week treatment with lixisenatide (or placebo) as add-on to basal insulin and metformin. The hypothesis of the study is that the glucagon counterregulation to hypoglycemia in patients treated with lixisenatide and basal insulin is not lower than in patients treated with basal insulin.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Effect of Lixisenatide on Glucagon Secretion During Hypoglycemia in Patients With Insulin-treated Type 2 Diabetes
Study Start Date : December 2013
Actual Primary Completion Date : August 2014
Actual Study Completion Date : August 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hypoglycemia

Arm Intervention/treatment
Experimental: Lixisenatide
Lixisenatide 20µg daily
Drug: Lixisenatide
Lixisenatide is given for 6 weeks whereafter a hypoglycemia clamp is undertaken
Other Name: Lyxumia

Primary Outcome Measures :
  1. Glucagon response to hypoglycemia [ Time Frame: 30 min ]
    Hypoglycemia is induced by clamp during 30 min; glucagon levels are measured during this time frame

Secondary Outcome Measures :
  1. Cortisol response to hypoglycemia [ Time Frame: 30 min ]
    Hypoglycemia is induced by a clamp during 30 min. Cortisol is measured during this time frame.

  2. Catecholamines [ Time Frame: 30 min ]
    Hypoglycemia is induced by a clamp during 30 min. Catecholamines are measured during this time frame.

Other Outcome Measures:
  1. HbA1c [ Time Frame: 6 weeks ]
    Change in HbA1c during six weeks treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male, non-fertile female or female of childbearing potential using a medically approved birth control method aged >18 years.
  2. Adult patients with type 2 diabetes treated with basal insulin (NPH insulin, insulin detemir, insulin glargine or insulin degludec) (stable insulin dose (±10%) during the last three months) with concomitant at >3 months stable dose (>1500 mg daily) of metformin.
  3. HbA1c <10% (DCCT standard; < 83 mmol(mol) at visit 1.

Exclusion Criteria:

  1. Treatment with antihyperglycemic agents apart from basal insulin and metformin, i.e., bolus insulin or other antihyperglycemic oral agents apart from metformin
  2. Type 1 diabetes (including LADA)
  3. Pregnant or lactating female. Women of childbearing potential with no effective contraceptive method. Acceptable contraceptive include contraceptive sponge; hormonal contraception pills, patches, vaginal rings, injectable contraceptives; and intrauterine devices. Women of childbearing potential (pre-menopausal, not surgically sterile women for at least 3 months prior to the time of screening) must have a confirmed negative serum pregnancy test at screening visit. They must use an effective contraceptive method throughout the study, and agree to repeat pregnancy tests at designated visits. The applied methods of contraception have to meet the criteria for a highly effective method of birth control according to the "Note for guidance on non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals (CPMP/ICH/286/95)"
  4. A history of any secondary forms of diabetes, e.g., Cushing's syndrome and acromegaly.
  5. Acute infections which may affect blood glucose control within 4 weeks prior to visit 1
  6. Any history of recent (<2 weeks) recurrent or severe hypoglycemic episodes or hypoglycemia unawareness
  7. Donation of one unit (500 ml) or more of blood, significant blood loss equaling to at least one unit of blood within the past 2 weeks or a blood transfusion within the past 8 weeks.
  8. Treatment with growth hormone and oral or parenteral corticosteroid (> 7 consecutive days of treatment) within 8 weeks prior to visit 1 and thereafter during the whole study period.
  9. Use of other investigational drugs within 30 days prior to visit 1.
  10. Laboratory findings at the time of screening, including amylase and/or lipase > 3 times the upper limit of the normal laboratory range (ULN) and P-calcitonin ≥20 pg/ml (5.9 pmol/L).
  11. Personal or immediate family history of medullary thyroid cancer (MTC) or genetic condition that predisposes to MTC (e.g. multiple endocrine neoplasia syndromes).
  12. History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery
  13. Allergic reaction to any GLP-1 receptor agonist or to metacresol
  14. Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting,
  15. Cardiovascular, hepatic, neurological, or endocrine disease, active malignant tumor or other major systemic disease or patients with short life expectancy making implementation of the protocol or interpretation of the study results difficult.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02020629

Layout table for location information
Clinical Research Department
Malmö, Sweden, 20502
Sponsors and Collaborators
Lund University
Layout table for investigator information
Principal Investigator: Bo Ahrén, MD, PhD Lund University
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bo Ahren, Professor, Lund University Identifier: NCT02020629    
Other Study ID Numbers: 16
2012-004959-36 ( EudraCT Number )
First Posted: December 25, 2013    Key Record Dates
Last Update Posted: December 15, 2015
Last Verified: December 2015
Keywords provided by Bo Ahren, Lund University:
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs